#### **ORIGINAL ARTICLE**



# Diffusion-weighted imaging for predicting tumor consistency and extent of resection in patients with pituitary adenoma

Wei Ding<sup>1</sup> · Zheng Huang<sup>1</sup> · Gaofeng Zhou<sup>2</sup> · Lang Li<sup>2</sup> · Mingyu Zhang<sup>1</sup> · Zhenyan Li<sup>1,3</sup>

Received: 5 August 2020 / Revised: 4 December 2020 / Accepted: 28 December 2020 / Published online: 28 January 2021 © The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021

#### Abstract

This study aimed to investigate the role of diffusion-weighted imaging (DWI) in predicting tumor consistency, extent of surgical resection, and recurrence in pituitary adenoma (PA). We reviewed a prospectively collected database of surgically treated PA between March 2016 and October 2017. Predictors for extent of resection and recurrence/progression were assessed with logistic and Cox regression analysis. Of the 183 patients, the tumor consistency was found soft in 107 (58.5%) patients, intermediate in 41 (22.4%) patients, and hard in 35 (19.1%) patients. The mean of ADC ratio was  $0.92 \pm 0.22$  for hard tumor,  $1.03 \pm 0.22$  for intermediate tumor, and  $1.41 \pm 0.62$  for soft tumor (P < 0.001). The mean collagen content was  $25.86\% \pm 15.00\%$  for hard tumor,  $16.05\% \pm 9.90\%$  for intermediate tumor, and  $5.00\% \pm 6.00\%$  for soft tumor (P < 0.001). Spearman analysis showed a significant correlation between ADC ratio and collagen content ( $\rho = -0.367$ ; P < 0.001). Gross-total resection (GTR) was obtained in 68.3% of patients, and multivariable logistic regression analysis showed that ADC ratio (OR, 12.135; 95% CI, 4.001-36.804; P < 0.001), giant PA (OR, 0.233; 95% CI, 0.105-0.520; P < 0.001), and invasion (OR, 0.459; 95% CI, 0.220-0.960; P = 0.039) were significantly predictive of GTR. Twenty-seven (14.8%) patients suffered recurrence/progression in the mean follow-up of 35.14 months. Invasion (HR, 2.728; 95% CI, 1.262-5.899; P = 0.011) was identified as independent predictors of recurrence/progression. ADC ratio of DWI could be used for preoperative assessment of tumor consistency, tumor collagen content, and extent of surgical resection, which might be useful in preoperative planning for patients with PA.

Keywords Pituitary adenoma · Diffusion-weighted imaging · Tumor consistency · Extent of resection · Recurrence

# Introduction

Pituitary adenoma (PA) is the third most common intracranial tumor, and the overall prevalence in general population was 16.7% [2]. Transsphenoidal endonasal surgery is preferred treatment in most patients with PA [13, 38]. Some factors that determine the extent of tumor resection included tumor size,

Co-first author: Wei Ding and Zheng Huang contribute equally to this work.

Zhenyan Li lizhenyan@csu.edu.cn

- <sup>1</sup> Department of Neurosurgery, Xiangya Hospital, Central South University, No.87 Xiangya Road, Kaifu District, Changsha 410008, China
- <sup>2</sup> Department of Radiology, Xiangya Hospital, Central South University, Changsha 410008, China
- <sup>3</sup> National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China

invasion of cavernous sinus (CS), and tumor consistency [3, 16, 20]. Fibrous tumor cannot be easily and sufficiently debulked by curettage and suction via this approach, and second-stage operation, transcranial surgery, or postoperative radiosurgery are often required [1]. Therefore, assessment of tumor consistency would help the clinicians to choose the best therapeutic strategies for patients with PA.

Diffusion-weighted imaging (DWI) in magnetic resonance imaging (MRI) provides information on tissue water diffusion, which is affected by the size and integrity of structures in the brain that normally restrict diffusion. In diffusion MRI, powerful magnetic gradients with echo planar sequence are used. This enables images that are dependent on water diffusion. A diffusion coefficient called apparent diffusion coefficient (ADC) value can be calculated, and ADC maps can be generated [14, 17, 23, 24, 30]. Several studies have reported DWI could be used to evaluate the tumor consistency [3, 4, 19, 26, 28, 32, 35, 36]. However, the relationship between apparent diffusion coefficient (ADC) value and tumor consistency remains uncertain because susceptibility artifacts would occur in the sellar region. Moreover, the ADC value used in predicting extent of resection and clinical outcomes was scarcely reported.

In this study, we prospectively collected the clinical, radiological, and histopathological data of patients with PA to discuss the role of DWI in preoperative evaluation of tumor consistency, extent of surgical resection, and recurrence.

# Methods

# Study design

The study protocol was approved by the Institutional Review Board of Xiangya Hospital. Written informed consent is obtained from all participants at admission. We reviewed a prospectively collected database of PA between March 2016 and October 2017 with the inclusion criteria as follows: (1) PA was diagnosis based on pathology and (2) patients were treated with transsphenoidal endoscopic endonasal surgery or transcranial surgery. Patients who received prior medical therapy, surgery, or radiosurgery were excluded. Recurrent PA, pituitary apoplexy, cystic pituitary adenoma, and microadenoma were also excluded.

# **Radiologic evaluation**

All patients underwent magnetic resonance imaging (MRI) before surgery, within 3 days postoperatively, 3 months postoperatively, and then at yearly intervals thereafter. MRI was performed using Signa excite 3.0T system (GE Medical Systems, Systems, Milwaukee, WI) including the following sequences: T1-weighted image with and without contrast, T2-weighted image, diffusion-weighted imaging (DWI) used for tumor consistency, and perfusion-weighted imaging (PWI) used for tumor blood supply [9]. Two experienced neuroradiologists (Gaofeng Zhou and Lang Li) who were blinded to clinical data evaluated MRI separately and resolved disagreement by consensus.

The SS-SE-EPI-DWI scan was acquired with a *b* value of 1000 using the following parameters: repetition time (TR) 5600 ms, echo time (TE) 76 ms, one excitation, matrix size  $160 \times 160$  mm, field of view (FOV)  $24 \times 24$  cm, bandwidth 250 Hz/pixel, thickness 4 mm, and intersection gap 1 mm. The parameters of GRE-PWI scan were as follows: TR1600ms, TE 25 ms, FOV  $24 \times 24$  cm, flip angle (FA) 90, matrix  $128 \times 128$ , bandwidth 250 Hz/pixel, thickness 4 mm, and intersection gap 1 mm. MRI data were transferred to a workstation (Advantage Workstation, AW4.2, GE Medical Systems), and the ADC was calculated with the Functool software (GE Medical Systems). Regions of interest (ROI) were placed on the solid parts of pituitary adenomas avoiding cystic or calcified areas and normal brainstem to measure the ADC

value on the ADC maps. ROI were placed on tumor and normal frontal white matter to measure values for four parameters, which included cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT), and time to peak (TTP). The neuroradiologist drew ROI of uniform shape and size (elliptic, 50 mm<sup>2</sup>) for three times and collected the mean value for final data. The ADC ratio was calculated as the ratio between mean ADC value in the tumor and that in the normal brainstem. The CBF ratio was calculated as the ratio between mean CBF value in the tumor and that in the normal frontal white matter.

Tumor size was measured according to maximal tumor diameter in the coronal plane of MRI, and giant adenoma was defined as tumor size over 40 mm. Invasion of the cavernous sinus was considered significant for grades III–IV on the Knosp classification [11, 18]. Sphenoid sinus invasion was defined as tumor growing into the sphenoid sinus confirmed on preoperative MRI or surgery. An invasive PA was considered in tumors with cavernous sinus or sphenoid sinus invasion [21]. The extent of resection was evaluated by comparing MRI before surgery with that within 3 days postoperatively and 3 months after surgery [7, 8, 16]. The extent of resection was categorized, according to the amount of tumor removed, as partial (< 50% volume removed), subtotal (50–80% volume removed), near-total resection (80–99% volume removed), and gross-total (100% volume removed) resection (GTR).

#### Surgical treatment

Surgical procedures included endoscopic endonasal transsphenoidal surgery and transcranial surgery which were performed by a senior neurosurgeon with over 10 years' experience in pituitary surgery. Transsphenoidal endoscopic endonasal surgery was the preferred approach to the vast majority patients unless patients have the following conditions: (1) parasellar tumor that extend far laterally beyond the internal carotid artery, project anteriorly onto the planum sphenoidale, or project laterally into the middle fossa is inaccessible from the transsphenoidal approach; (2) tumor is fibrous and adheres firmly to critical structures which is difficult to remove totally via the transsphenoidal approach; and (3) prolonged sphenoid sinus inflammation. If tumor cannot be totally removed after surgery, intervention including gamma knife radiosurgery, repeat resection, and medical therapy would be recommended based on patients' condition and tumor characteristics.

Surgical navigation systems (StealthStation® S7; Medtronic, Inc.) and Mini-Doppler (the ES100X MiniDop®; Koven Technology, Inc.) were used to identify the internal carotid artery and guide the extent of bony resection. Soft PA was removed by suction and ring curettes, and for harder tumor, it requires piecemeal resection using a micro-dissector or tumor forceps. The consistency of the tumor was evaluated by the surgeon as soft (easily removable through suction), intermediate (removed by suction with difficulty), or hard (not removable by suction and excised en bloc) [28]. The tumor blood supply was classified as rich (large amount of bleeding during tumor resection that influences the clearance of surgical field), medium (bleeding is observed during tumor section which does not obviously influence the clearance of surgical field), and poor (no obvious bleeding occurred during tumor section) [22].

# Histopathological assessment

Tissue samples were examined histologically by two experienced pathologists (with 10 years of experience in neuropathology), who were blinded to clinical and radiologic data. Histopathologic examination included hematoxylin-eosin (HE) stain, MIB-1 labeling index (Ki-67), and routine immunohistochemical analysis for pituitary hormones. Masson trichrome staining was used for testing collagen content in which collagen fibers stained as blue. Collagen-containing area and the total tumor area were measured with the Image J software, and the percent of collagen content was calculated using the formula: ∑collagen area/∑total tumor area\*100%.

# **Clinical follow-up**

Patients were clinically evaluated within 30 days after surgery, in 3 months postoperatively and at the last follow-up. After discharge, the patients were followed up in the outpatient clinic and at home by telephone or visit. All outcomes were evaluated by a trained physician not directly involved in the care of these patients and blinded to the patient's clinical data. The clinical outcome was evaluated based on tumor recurrence and progression [21, 27]. Recurrence of PA was defined as evidence of a tumor mass on MRI scan during follow-up after GTR. Furthermore, the recurrence of functional PA was also determined by the reappearance of hormonal hypersecretion after normalization. Tumor progression was defined as evidence of regrowth of residual on MRI and/or an increase in plasma hormone levels.

#### **Statistical analysis**

Data were analyzed using the IBM SPSS Statistics software (Version 20.0). Statistical significance was set at P < 0.05. Values were shown in the form of mean ± standard deviation (SD) for normally distributed data or median for data that were skewedly distributed. Fisher's exact test or Pearson  $\chi^2$  test was used for comparison of categorical variables, and quantitative variables were compared using independent Student's *t* test, analysis of variance, or Kruskal–Wallis test. Spearman correlation coefficients were calculated between ADC ratio and collagen content. Predictors for GTR of tumor were analyzed

using logistic regression model, and the Cox regression model was used to determine the significance of variables in predicting recurrence and progression.

# Results

# **Patient characteristics**

Demographic and radiological baselines are shown in Table 1. A total of 183 patients were enrolled. There were 102 (55.7%) females and 81 (44.3%) males in all patients with mean age of 46.74 years (range, 17–72 years). The most common symptoms were visual impairment in 66 (36.1%) patients, headache in 40 (21.9%) patients, endocrine dysfunction in 53 (29.0%) patients, and incidental finding on MRI in 24 (13.1%) patients. The clinical presentations, preoperative endocrinologic test, and histopathological assessment showed 64 (35.0%) patients with functional PA. Giant tumor was found in 48 (26.2%) patients, and invasiveness of tumor was evident for 38.3% of patients.

# Tumor consistency and blood flow

The tumor consistency was found soft in 107 (58.5%) patients, intermediate in 41 (22.4%) patients, and hard in 35 (19.1%) patients (Figs. 1, 2, and 3). The mean ADC value of PA was  $0.69 \pm 0.16$  mm<sup>2</sup>/s for patients with hard tumor,  $0.76 \pm$ 0.17mm<sup>2</sup>/s for patients with intermediate tumor, and  $1.00 \pm$ 0.39 mm<sup>2</sup>/s for patients with soft tumor, respectively. The average of ADC ratio was  $0.92 \pm 0.22$  for patients with hard tumor,  $1.03 \pm 0.22$  for patients with intermediate tumor, and  $1.41 \pm 0.62$  for patients with soft tumor, respectively (P < 0.001). The mean collagen content was  $25.86 \pm 15.00\%$  for patients with hard tumor,  $16.05 \pm 9.90\%$  for patients with intermediate tumor, and  $5.00 \pm 6.00\%$  for patients with soft tumor, respectively (P < 0.001). Spearman showed a significant correlation between rADC and collagen content ( $\rho = -$ 0.367; P < 0.001). The tumor blood flow was found rich in 116 (63.4%) patients, medium in 64 (35.0%) patients, and poor in 3 (1.6%) patients. The mean CBF ratio was 1.67  $\pm$ 1.03 for patients with rich tumor and  $1.05 \pm 0.54$  for patients with medium and poor tumor (P < 0.001).

#### Outcomes

All patients underwent surgical treatment including 169 patients treated with endoscopic endonasal transsphenoidal surgery and 14 patients treated with transcranial approach. GTR was obtained in 68.3% of patients, near-total resection in 28.4% of patients, and subtotal resection in 3.3% of patients. Clinical and radiological features on extent of resection are shown in Supplementary Table S1. There was one (0.5%)

Table 1 Clinical characteristics in 183 patients with pituitary adenoma

Age (years) $49.00 \pm 20.00^*$ Sex (female/male)         Female $102 (55.7\%)$ Male $81 (44.3\%)$ Initial clinical presentations           Headache $40 (21.8\%)$ Visual disorder $66 (36.1\%)$ Endocrine dysfunction $53 (29.0\%)$ Asymptomatically $24 (13.1\%)$ Hormone type (functional PA) $64 (35.2\%)$ Knosp classification $0$ $56 (30.6\%)$ 1 $34 (18.6\%)$ $2$ $22 (12.0\%)$ $4$ $35 (19.1\%)$ Sphenoid sinus invasion $43 (23.5\%)$ Invasive pituitary adenoma $70 (38.2\%)$ Tumor size $<40 \text{ mm}$ $135 (73.8\%)$ $24 (10.1\%) 240 \text{ mm} 135 (19.1\%)         Intermediate         41 (22.4\%)           Soft         107 (58.5\%) 0.87 \pm 0.44*           ADC ratio         1.19 \pm 0.60*         Masson's trichrome staining (%)         9.00 \pm 14.00           Tumor blood flow         Rich         116 (63.4\%)         Medium and poor         67 (36.6\%)           CBF ratio         1.41 \pm 1.05*         Surgical approach         125 (68.3\%)         Near-total resection         52 (28.4\%) $	Variables	n (%)
Sex (female/male) Female 102 (55.7%) Male 102 (55.7%) Male 102 (55.7%) Male 102 (55.7%) Male 102 (55.7%) Nature 102 (55.7%) Nature 102 (55.7%) Nature 102 (55.7%) Headache 40 (21.8%) Visual disorder 66 (36.1%) Endocrine dysfunction 53 (29.0%) Asymptomatically 24 (13.1%) Hormone type (functional PA) 66 (35.2%) Knosp classification $0$ 0 56 (30.6%) 1 34 (18.6%) 2 36 (19.7%) 3 40 (18.6%) 2 20 (20.0%) 4 35 (19.1%) Sphenoid sinus invasion 43 (23.5%) Invasive pituitary adenoma 70 (38.2%) Tumor size < 40 mm 135 (73.8%) ≥ 40 mm 135 (73.8%) ≥ 40 mm 135 (73.8%) ≥ 40 mm 35 (79.1%) Intermediate 41 (22.4%) Soft 107 (58.5%) ADC ratio 1.19 ± 0.60* Masson's trichrome staining (%) 9.00 ± 14.00 Tumor blood flow Rich 116 (63.4%) Medium and poor 67 (36.6%) CBF ratio 1.41 ± 1.05* Surgical approach Transsphenoidal endoscopic surgery 169 (93.35%) Transcranial surgery 14 (7.65%) Extent of resection 52 (28.4%) Subtotal resection 63 (3%) Follow-up outcome Facurrence 14 (7.7%) Progression 13 (7.1%)	Age (years)	$49.00 \pm 20.00^{*}$
Female       102 (55.7%)         Male       81 (44.3%)         Initial clinical presentations       40 (21.8%)         Visual disorder       66 (36.1%)         Endocrine dysfunction       53 (29.0%)         Asymptomatically       24 (13.1%)         Hormone type (functional PA)       64 (35.2%)         Knosp classification       0         0       56 (30.6%)         1       34 (18.6%)         2       36 (19.7%)         3       22 (12.0%)         4       35 (19.1%)         Sphenoid sinus invasion       43 (23.5%)         Invasive pituitary adenoma       70 (38.2%)         Tumor size $< 40$ mm       135 (73.8%) $\ge 40$ mm       48 (26.2%)         Tumor consistency       Intermediate         Hard       35 (19.1%)         Intermediate       41 (22.4%)         Soft       107 (58.5%)         ADC ratio       1.19 $\pm$ 0.60*         Masson's trichrome staining (%)       9.00 $\pm$ 14.00         Tumor blood flow       Itich         Rich       116 (63.4%)         Medium and poor       67 (36.6%)         CBF ratio       1.41 $\pm$ 1.05* <td>Sex (female/male)</td> <td></td>	Sex (female/male)	
Male $81 (44.3\%)$ Initial clinical presentationsHeadache $40 (21.8\%)$ Visual disorder $66 (36.1\%)$ Endocrine dysfunction $53 (29.0\%)$ Asymptomatically $24 (13.1\%)$ Hormone type (functional PA) $64 (35.2\%)$ Knosp classification $0$ 0 $56 (30.6\%)$ 1 $34 (18.6\%)$ 2 $36 (19.7\%)$ 3 $22 (12.0\%)$ 4 $35 (19.1\%)$ Sphenoid sinus invasion $43 (23.5\%)$ Invasive pituitary adenoma $70 (38.2\%)$ Tumor size $<40 \text{ mm}$ $<40 \text{ mm}$ $135 (73.8\%)$ $\ge 40 \text{ mm}$ $48 (26.2\%)$ Tumor consistency $Hard$ Hard $35 (19.1\%)$ Intermediate $41 (22.4\%)$ Soft $107 (58.5\%)$ ADC tumor (mm <sup>2</sup> /s) $0.87 \pm 0.44*$ ADC tratio $1.19 \pm 0.60*$ Masson's trichrome staining (%) $9.00 \pm 14.00$ Tumor blood flow $Rich$ Rich $116 (63.4\%)$ Medium and poor $67 (36.6\%)$ CBF ratio $1.41 \pm 1.05*$ Surgical approach $125 (68.3\%)$ Transsphenoidal endoscopic surgery $169 (93.35\%)$ Transsphenoidal endoscopic surgery $169 (9$	Female	102 (55.7%)
Initial clinical presentationsHeadache40 (21.8%)Visual disorder66 (36.1%)Endocrine dysfunction53 (29.0%)Asymptomatically24 (13.1%)Hormone type (functional PA)64 (35.2%)Knosp classification0056 (30.6%)134 (18.6%)236 (19.7%)322 (12.0%)435 (19.1%)Sphenoid sinus invasion43 (23.5%)Invasive pituitary adenoma70 (38.2%)Tumor size< 40 mm	Male	81 (44.3%)
Headache $40 (21.8\%)$ Visual disorder $66 (36.1\%)$ Endocrine dysfunction $53 (29.0\%)$ Asymptomatically $24 (13.1\%)$ Hormone type (functional PA) $64 (35.2\%)$ Knosp classification $0$ $0$ $56 (30.6\%)$ 1 $34 (18.6\%)$ 2 $36 (19.7\%)$ 3 $22 (12.0\%)$ $4$ $35 (19.1\%)$ Sphenoid sinus invasion $43 (23.5\%)$ Invasive pituitary adenoma $70 (38.2\%)$ Tumor size $<40 \text{ mm}$ $<40 \text{ mm}$ $135 (73.8\%)$ $\geq 40 \text{ mm}$ $48 (26.2\%)$ Tumor consistency $Hard$ Hard $35 (19.1\%)$ Intermediate $41 (22.4\%)$ Soft $107 (58.5\%)$ ADC ratio $1.19 \pm 0.60^*$ Masson's trichrome staining (%) $9.00 \pm 14.00$ Tumor blood flow $Rich$ Rich $116 (63.4\%)$ Medium and poor $67 (36.6\%)$ CBF ratio $1.41 \pm 1.05^*$ Surgical approach $Transsphenoidal endoscopic surgery$ If or esection $125 (68.3\%)$ Near-total resection $52 (28.4\%)$ Subtotal resection $52 (28.4\%)$ Subtotal resection $6 (3.3\%)$ Follow-up outcome $Recurrence$ Recurrence $14 (7.7\%)$ Progression $13 (7.1\%)$	Initial clinical presentations	
Visual disorder $66 (36.1\%)$ Endocrine dysfunction $53 (29.0\%)$ Asymptomatically $24 (13.1\%)$ Hormone type (functional PA) $64 (35.2\%)$ Knosp classification $0$ 0 $56 (30.6\%)$ 1 $34 (18.6\%)$ 2 $36 (19.7\%)$ 3 $22 (12.0\%)$ 4 $35 (19.1\%)$ Sphenoid sinus invasion $43 (23.5\%)$ Invasive pituitary adenoma $70 (38.2\%)$ Tumor size $<40 \text{ mm}$ $<40 \text{ mm}$ $135 (73.8\%)$ $\ge 40 \text{ mm}$ $48 (26.2\%)$ Tumor consistency       Hard         Hard $35 (19.1\%)$ Intermediate $41 (22.4\%)$ Soft $107 (58.5\%)$ ADC ratio $1.19 \pm 0.60^*$ Masson's trichrome staining (%) $9.00 \pm 14.00$ Tumor blood flow       Rich $116 (63.4\%)$ Medium and poor $67 (36.6\%)$ CBF ratio $1.41 \pm 1.05^*$ Surgical approach       Transcranial surgery         Transcranial surgery $14 (7.65\%)$ Extent of r	Headache	40 (21.8%)
Endocrine dysfunction       53 (29.0%)         Asymptomatically       24 (13.1%)         Hormone type (functional PA)       64 (35.2%)         Knosp classification       0         0       56 (30.6%)         1       34 (18.6%)         2       36 (19.7%)         3       22 (12.0%)         4       35 (19.1%)         Sphenoid sinus invasion       43 (23.5%)         Invasive pituitary adenoma       70 (38.2%)         Tumor size          < 40 mm	Visual disorder	66 (36.1%)
Asymptomatically       24 (13.1%)         Hormone type (functional PA)       64 (35.2%)         Knosp classification       3         0       56 (30.6%)         1       34 (18.6%)         2       36 (19.7%)         3       22 (12.0%)         4       35 (19.1%)         Sphenoid sinus invasion       43 (23.5%)         Invasive pituitary adenoma       70 (38.2%)         Tumor size          < 40 mm	Endocrine dysfunction	53 (29.0%)
Hormone type (functional PA)       64 (35.2%)         Knosp classification       0         0       56 (30.6%)         1       34 (18.6%)         2       36 (19.7%)         3       22 (12.0%)         4       35 (19.1%)         Sphenoid sinus invasion       43 (23.5%)         Invasive pituitary adenoma       70 (38.2%)         Tumor size          < 40 mm	Asymptomatically	24 (13.1%)
Knosp classification $0$ 56 (30.6%)         1       34 (18.6%)         2       36 (19.7%)         3       22 (12.0%)         4       35 (19.1%)         Sphenoid sinus invasion       43 (23.5%)         Invasive pituitary adenoma       70 (38.2%)         Tumor size          < 40 mm	Hormone type (functional PA)	64 (35.2%)
0       56 (30.6%)         1       34 (18.6%)         2       36 (19.7%)         3       22 (12.0%)         4       35 (19.1%)         Sphenoid sinus invasion       43 (23.5%)         Invasive pituitary adenoma       70 (38.2%)         Tumor size          < 40 mm	Knosp classification	
1       34 (18.6%)         2       36 (19.7%)         3       22 (12.0%)         4       35 (19.1%)         Sphenoid sinus invasion       43 (23.5%)         Invasive pituitary adenoma       70 (38.2%)         Tumor size       <40 mm	0	56 (30.6%)
2 $36 (19.7\%)$ 3 $22 (12.0\%)$ 4 $35 (19.1\%)$ Sphenoid sinus invasion $43 (23.5\%)$ Invasive pituitary adenoma $70 (38.2\%)$ Tumor size $<40  \text{nm}$ $<40  \text{nm}$ $135 (73.8\%)$ $≥ 40  \text{nm}$ $48 (26.2\%)$ Tumor consistency $48 (26.2\%)$ Hard $35 (19.1\%)$ Intermediate $41 (22.4\%)$ Soft $107 (58.5\%)$ ADC tumor (mm²/s) $0.87 \pm 0.44*$ ADC ratio $1.19 \pm 0.60*$ Masson's trichrome staining (%) $9.00 \pm 14.00$ Tumor blood flow $Rich$ $116 (63.4\%)$ Medium and poor $67 (36.6\%)$ $CBF$ ratio         Transsphenoidal endoscopic surgery $169 (93.35\%)$ Transcranial surgery $14 (7.5\%)$ Extent of resection $52 (28.4\%)$ Subtotal resection $52 (28.4\%)$ Subtotal resection $52 (28.4\%)$ Subtotal resection $6 (3.3\%)$ Follow-up outcome       Recurrence         Recurrence $14 (7.7\%)$ Progression <td>1</td> <td>34 (18.6%)</td>	1	34 (18.6%)
3       22 (12.0%)         4       35 (19.1%)         Sphenoid sinus invasion       43 (23.5%)         Invasive pituitary adenoma       70 (38.2%)         Tumor size          < 40 mm	2	36 (19.7%)
435 (19.1%)Sphenoid sinus invasion43 (23.5%)Invasive pituitary adenoma70 (38.2%)Tumor size70 (38.2%)< 40 mm	3	22 (12.0%)
Sphenoid sinus invasion43 (23.5%)Invasive pituitary adenoma70 (38.2%)Tumor size $<40 \text{ mm}$ $<40 \text{ mm}$ 135 (73.8%) $\geq 40 \text{ mm}$ 48 (26.2%)Tumor consistency $41 (22.4\%)$ Hard35 (19.1%)Intermediate41 (22.4%)Soft107 (58.5%)ADC tumor (mm²/s) $0.87 \pm 0.44*$ ADC ratio $1.19 \pm 0.60*$ Masson's trichrome staining (%) $9.00 \pm 14.00$ Tumor blood flow $116 (63.4\%)$ Rich116 (63.4%)Medium and poor67 (36.6%)CBF ratio $1.41 \pm 1.05*$ Surgical approach $125 (68.3\%)$ Transsphenoidal endoscopic surgery169 (93.35%)Transcranial surgery14 (7.65%)Extent of resection $52 (28.4\%)$ Subtotal resection $52 (28.4\%)$ Subtotal resection $52 (28.4\%)$ Follow-up outcome $14 (7.7\%)$ Progression13 (7.1\%)	4	35 (19.1%)
Invasive pituitary adenoma70 (38.2%)Tumor size135 (73.8%) $\geq$ 40 mm135 (73.8%) $\geq$ 40 mm48 (26.2%)Tumor consistency41 (22.4%)Hard35 (19.1%)Intermediate41 (22.4%)Soft107 (58.5%)ADC tumor (mm²/s)0.87 ± 0.44*ADC ratio1.19 ± 0.60*Masson's trichrome staining (%)9.00 ± 14.00Tumor blood flow116 (63.4%)Rich116 (63.4%)Medium and poor67 (36.6%)CBF ratio1.41 ± 1.05*Surgical approach14 (7.65%)Extent of resection125 (68.3%)Near-total resection52 (28.4%)Subtotal resection52 (28.4%)Subtotal resection6 (3.3%)Follow-up outcome14 (7.7%)Progression13 (7.1%)	Sphenoid sinus invasion	43 (23.5%)
Tumor size135 (73.8%) $< 40 \text{ mm}$ 135 (73.8%) $\geq 40 \text{ mm}$ 48 (26.2%)Tumor consistency41 (22.4%)Hard35 (19.1%)Intermediate41 (22.4%)Soft107 (58.5%)ADC tumor (mm²/s) $0.87 \pm 0.44*$ ADC ratio $1.19 \pm 0.60*$ Masson's trichrome staining (%) $9.00 \pm 14.00$ Tumor blood flow $Rich$ Rich116 (63.4%)Medium and poor67 (36.6%)CBF ratio $1.41 \pm 1.05*$ Surgical approach $T$ Transsphenoidal endoscopic surgery169 (93.35%)Transcranial surgery14 (7.65%)Extent of resection $52$ (28.4%)Subtotal resection $52$ (28.4%)Subtotal resection $6$ (3.3%)Follow-up outcome $Recurrence$ Recurrence $14$ (7.7%)Progression13 (7.1%)	Invasive pituitary adenoma	70 (38.2%)
$< 40 \text{ mm}$ 135 (73.8%) $\geq 40 \text{ mm}$ 48 (26.2%)Tumor consistency48 (26.2%)Hard35 (19.1%)Intermediate41 (22.4%)Soft107 (58.5%)ADC tumor (mm²/s)0.87 ± 0.44*ADC ratio1.19 ± 0.60*Masson's trichrome staining (%)9.00 ± 14.00Tumor blood flow116 (63.4%)Medium and poor67 (36.6%)CBF ratio1.41 ± 1.05*Surgical approach14 (7.65%)Transsphenoidal endoscopic surgery169 (93.35%)Transcranial surgery14 (7.65%)Extent of resection52 (28.4%)Subtotal resection52 (28.4%)Subtotal resection6 (3.3%)Follow-up outcome14 (7.7%)Progression13 (7.1%)	Tumor size	
≥ 40  mm $ 48 (26.2%) $ Tumor consistency $ Hard $ $ 35 (19.1%) $ Intermediate 41 (22.4%)  Soft $ 107 (58.5\%) $ $ ADC_{tumor} (mm^2/s) $ $ 0.87 \pm 0.44^* $ $ ADC ratio $ $ 1.19 \pm 0.60^* $ $ Masson's trichrome staining (%) $ $ 9.00 \pm 14.00 $ $ Tumor blood flow $ $ Rich $ $ 116 (63.4\%) $ $ Medium and poor $ $ 67 (36.6\%) $ $ CBF ratio $ $ 1.41 \pm 1.05^* $ $ Surgical approach $ $ Transsphenoidal endoscopic surgery $ $ 169 (93.35\%) $ $ Transcranial surgery $ $ 125 (68.3\%) $ $ Near-total resection $ $ 52 (28.4\%) $ $ Subtotal resection $ $ 52 (28.4\%) $ $ Subtotal resection $ $ 6 (3.3\%) $ $ Follow-up outcome $ $ Recurrence $ $ 14 (7.7\%) $ $ Progression $ $ 13 (7.1\%) $	< 40 mm	135 (73.8%)
Tumor consistency $35 (19.1\%)$ Intermediate $35 (19.1\%)$ Soft $107 (58.5\%)$ ADC tumor (mm²/s) $0.87 \pm 0.44*$ ADC ratio $1.19 \pm 0.60*$ Masson's trichrome staining (%) $9.00 \pm 14.00$ Tumor blood flow $8.66 + 0.00*$ Rich $116 (63.4\%)$ Medium and poor $67 (36.6\%)$ CBF ratio $1.41 \pm 1.05*$ Surgical approach $14 (7.65\%)$ Transcranial surgery $169 (93.35\%)$ Transcranial surgery $165 (68.3\%)$ Near-total resection $125 (68.3\%)$ Near-total resection $52 (28.4\%)$ Subtotal resection $52 (28.4\%)$ Subtotal resection $52 (28.4\%)$ Subtotal resection $6 (3.3\%)$ Follow-up outcome $Recurrence$ Recurrence $14 (7.7\%)$ Progression $13 (7.1\%)$	$\geq$ 40 mm	48 (26.2%)
Hard $35 (19.1\%)$ Intermediate $41 (22.4\%)$ Soft $107 (58.5\%)$ ADC turnor (mm²/s) $0.87 \pm 0.44*$ ADC ratio $1.19 \pm 0.60*$ Masson's trichrome staining (%) $9.00 \pm 14.00$ Tumor blood flow       Rich $116 (63.4\%)$ Medium and poor $67 (36.6\%)$ CBF ratio         CBF ratio $1.41 \pm 1.05*$ Surgical approach       Transsphenoidal endoscopic surgery $169 (93.35\%)$ Transcranial surgery $14 (7.65\%)$ Extent of resection $52 (28.4\%)$ Subtotal resection $52 (28.4\%)$ Subtotal resection $6 (3.3\%)$ Follow-up outcome $Recurrence$ $14 (7.7\%)$ Progression $13 (7.1\%)$	Tumor consistency	
Intermediate $41 (22.4\%)$ Soft $107 (58.5\%)$ ADC tumor (mm²/s) $0.87 \pm 0.44^*$ ADC ratio $1.19 \pm 0.60^*$ Masson's trichrome staining (%) $9.00 \pm 14.00$ Tumor blood flow       Rich         Rich $116 (63.4\%)$ Medium and poor $67 (36.6\%)$ CBF ratio $1.41 \pm 1.05^*$ Surgical approach       Transsphenoidal endoscopic surgery         Transcranial surgery $169 (93.35\%)$ Transcranial surgery $14 (7.65\%)$ Extent of resection $52 (28.4\%)$ Subtotal resection $52 (28.4\%)$ Subtotal resection $6 (3.3\%)$ Follow-up outcome $Recurrence$ Recurrence $14 (7.7\%)$ Progression $13 (7.1\%)$	Hard	35 (19.1%)
Soft       107 (58.5%)         ADC $_{turnor}$ (mm²/s) $0.87 \pm 0.44^*$ ADC ratio $1.19 \pm 0.60^*$ Masson's trichrome staining (%) $9.00 \pm 14.00$ Tumor blood flow       Rich         Rich       116 (63.4%)         Medium and poor       67 (36.6%)         CBF ratio $1.41 \pm 1.05^*$ Surgical approach       Transsphenoidal endoscopic surgery         Transsphenoidal endoscopic surgery       169 (93.35%)         Transcranial surgery       14 (7.65%)         Extent of resection       52 (28.4%)         Subtotal resection       52 (28.4%)         Subtotal resection       6 (3.3%)         Follow-up outcome       Recurrence         Recurrence       14 (7.7%)         Progression       13 (7.1%)	Intermediate	41 (22.4%)
$ADC_{tumor} (mm^2/s)$ $0.87 \pm 0.44^*$ $ADC$ ratio $1.19 \pm 0.60^*$ Masson's trichrome staining (%) $9.00 \pm 14.00$ Tumor blood flow $8.00 \pm 14.00$ Rich $116 (63.4\%)$ Medium and poor $67 (36.6\%)$ CBF ratio $1.41 \pm 1.05^*$ Surgical approach $1.41 \pm 1.05^*$ Transsphenoidal endoscopic surgery $169 (93.35\%)$ Transcranial surgery $14 (7.65\%)$ Extent of resection $125 (68.3\%)$ Near-total resection $52 (28.4\%)$ Subtotal resection $6 (3.3\%)$ Follow-up outcome $Recurrence$ Recurrence $14 (7.7\%)$ Progression $13 (7.1\%)$	Soft	107 (58.5%)
ADC ratio $1.19 \pm 0.60^*$ Masson's trichrome staining (%) $9.00 \pm 14.00$ Tumor blood flow $116 (63.4\%)$ Rich $116 (63.4\%)$ Medium and poor $67 (36.6\%)$ CBF ratio $1.41 \pm 1.05^*$ Surgical approach $141 \pm 1.05^*$ Transsphenoidal endoscopic surgery $169 (93.35\%)$ Transcranial surgery $14 (7.65\%)$ Extent of resection $25 (68.3\%)$ Near-total resection $52 (28.4\%)$ Subtotal resection $6 (3.3\%)$ Follow-up outcome $14 (7.7\%)$ Progression $13 (7.1\%)$	$ADC_{tumor} (mm^2/s)$	$0.87 \pm 0.44*$
Masson's trichrome staining (%) $9.00 \pm 14.00$ Tumor blood flow116 (63.4%)Rich116 (63.4%)Medium and poor67 (36.6%)CBF ratio $1.41 \pm 1.05^*$ Surgical approach141 $\pm 1.05^*$ Transsphenoidal endoscopic surgery169 (93.35%)Transcranial surgery14 (7.65%)Extent of resection25 (68.3%)Near-total resection52 (28.4%)Subtotal resection6 (3.3%)Follow-up outcome14 (7.7%)Progression13 (7.1%)	ADC ratio	$1.19 \pm 0.60*$
Tumor blood flow116 (63.4%)Rich116 (63.4%)Medium and poor $67 (36.6\%)$ CBF ratio $1.41 \pm 1.05^*$ Surgical approach141 $\pm 1.05^*$ Transsphenoidal endoscopic surgery169 (93.35%)Transcranial surgery14 (7.65%)Extent of resection125 (68.3%)Near-total resection52 (28.4%)Subtotal resection6 (3.3%)Follow-up outcome14 (7.7%)Progression13 (7.1%)	Masson's trichrome staining (%)	$9.00 \pm 14.00$
Rich         116 (63.4%)           Medium and poor         67 (36.6%)           CBF ratio         1.41 ± 1.05*           Surgical approach         141 ± 1.05*           Transsphenoidal endoscopic surgery         169 (93.35%)           Transcranial surgery         14 (7.65%)           Extent of resection         125 (68.3%)           Near-total resection         52 (28.4%)           Subtotal resection         6 (3.3%)           Follow-up outcome         14 (7.7%)           Progression         13 (7.1%)	Tumor blood flow	
Medium and poor $67 (36.6\%)$ CBF ratio $1.41 \pm 1.05^*$ Surgical approach $1.41 \pm 1.05^*$ Transsphenoidal endoscopic surgery $169 (93.35\%)$ Transcranial surgery $14 (7.65\%)$ Extent of resection $125 (68.3\%)$ Mear-total resection $52 (28.4\%)$ Subtotal resection $6 (3.3\%)$ Follow-up outcome $14 (7.7\%)$ Progression $13 (7.1\%)$	Rich	116 (63.4%)
CBF ratio $1.41 \pm 1.05^*$ Surgical approach169 (93.35%)Transsphenoidal endoscopic surgery169 (93.35%)Transcranial surgery14 (7.65%)Extent of resection125 (68.3%)Mear-total resection52 (28.4%)Subtotal resection6 (3.3%)Follow-up outcome14 (7.7%)Progression13 (7.1%)	Medium and poor	67 (36.6%)
Surgical approach Transsphenoidal endoscopic surgery 169 (93.35%) Transcranial surgery 14 (7.65%) Extent of resection Gross-total resection 125 (68.3%) Near-total resection 52 (28.4%) Subtotal resection 6 (3.3%) Follow-up outcome Recurrence 14 (7.7%) Progression 13 (7.1%)	CBF ratio	$1.41 \pm 1.05*$
Transsphenoidal endoscopic surgery169 (93.35%)Transcranial surgery14 (7.65%)Extent of resection125 (68.3%)Gross-total resection52 (28.4%)Subtotal resection6 (3.3%)Follow-up outcome14 (7.7%)Progression13 (7.1%)	Surgical approach	
Transcranial surgery14 (7.65%)Extent of resection125 (68.3%)Gross-total resection52 (28.4%)Subtotal resection6 (3.3%)Follow-up outcome14 (7.7%)Progression13 (7.1%)	Transsphenoidal endoscopic surgery	169 (93.35%)
Extent of resection125 (68.3%)Gross-total resection52 (28.4%)Near-total resection52 (28.4%)Subtotal resection6 (3.3%)Follow-up outcome14 (7.7%)Progression13 (7.1%)	Transcranial surgery	14 (7.65%)
Gross-total resection125 (68.3%)Near-total resection52 (28.4%)Subtotal resection6 (3.3%)Follow-up outcome14 (7.7%)Progression13 (7.1%)	Extent of resection	
Near-total resection52 (28.4%)Subtotal resection6 (3.3%)Follow-up outcome14 (7.7%)Progression13 (7.1%)	Gross-total resection	125 (68.3%)
Subtotal resection6 (3.3%)Follow-up outcome14 (7.7%)Progression13 (7.1%)	Near-total resection	52 (28.4%)
Follow-up outcomeRecurrence14 (7.7%)Progression13 (7.1%)	Subtotal resection	6 (3.3%)
Recurrence         14 (7.7%)           Progression         13 (7.1%)	Follow-up outcome	
Progression 13 (7.1%)	Recurrence	14 (7.7%)
_	Progression	13 (7.1%)

\*Values are presented with median  $\pm$  QR

CI confidence interval, PA pituitary adenoma

perioperative death due to intracranial infection, and the tumor of this patient was near-total resection. Complications included five patients (2.7%) with cerebrospinal fluid leaks, two patients (1.1%) with bleeding, one (0.5%) patient with intracranial infection, one (0.5%) patient with visual deterioration, twelve (6.6%) patients with diabetes insipidus, and seven (3.8%) patients with new hypopituitarism.

The mean follow-up period was 35.14 months (range, 24–42 months). Twenty-seven (14.8%) patients suffered recurrence or progression (Supplementary Table S2). Of these patients, 4 patients were performed with second surgery, 16 patients underwent adjuvant gamma knife radiosurgery, 2 patients treated with medical therapy, and 5 patients chose observation.

# Predictors for extent of surgical resection and recurrence/progression

The predictors for extent of surgical resection and recurrence/ progression are shown in Table 2. Multivariable logistic regression analysis showed that ADC ratio (OR, 12.135; 95% CI, 4.001–36.804; P < 0.001), giant PA (OR, 0.233; 95% CI, 0.105–0.520; P < 0.001), and invasion (OR, 0.459; 95% CI, 0.220–0.960; P = 0.039) were significantly predictive of GTR. Invasion (HR, 2.728; 95% CI, 1.262–5.899; P =0.011) was identified as independent predictors of recurrence or progression at the last follow-up.

# Discussion

Surgical resection is the main treatment for patient with PA [13, 38]. Previous studies revealed that 26.3–40.1% patients suffered recurrence or progression after surgery [12, 29], and incomplete resection was one of the predictors for recurrence [21]. Some tumor characteristics, such as soft consistency, were significantly associated with gross total resection [5]. Therefore, identification of tumor characteristics related to GTR and post-operative recurrence/progression is important to facilitate clinical decision making. Our study reviewed 183 patients with PA and revealed that ADC ratio of DWI could be used for preoperative assessment of tumor consistency, tumor collagen content, and extent of surgical resection, which might be useful in preoperative planning for patients with PA.

It is still controversial the relationship between the tumor consistency and ADC value in DWI. Suzuki et al. [32], Yiping et al. [36], and Alimohamadi et al. [4] found no significant correction between tumor consistency and ADC value. Mohamed et al. [26] found that higher absolute ADC value was associated with hard consistency. Pierallini et al. [28] and Wei et al. [35] reported that higher ADC ratio value was significantly predictive of soft tumor, which was consistent with our study, while Boxerman et al. [10] found that higher ADC ratio was associated with hard tumor. The reasons on different results of abovementioned studies are as follows. First, besides our study, the sample size in other studies was small. In addition, due to low incidence of hard PA (the

Fig. 1 A 27-year-old male with a hard pituitary adenoma. The tumor in the sellar region is isointense on coronal T1weighted imaging (a), relatively hyperintense on coronal T2weighted imaging (b), slightly enhanced on coronal enhanced T1-wighted imaging (c), and relatively hypointense on apparent diffusion coefficient map (d). Pituitary adenoma is confirmed by postoperative hematoxylin-eosin staining (e), and abundant collagen content (in blue) is found in Masson trichrome staining showed (f)



reported incidence of 10-24.5%) [4, 25, 37], the number of patients with hard tumor in most studies was limited. Second, different DWI techniques and parameters were used in these studies. Su et al. discussed DWI at a standard b value (b =  $1000 \text{s/mm}^2$ ) and a high b value (b =  $2000 \text{s/mm}^2$ ) for their ability to assess the tumor consistency of pituitary macroadenomas and found ADC at a high b value may facilitate better type discrimination [31]. Third, values on ADC map for predicting tumor consistency were differently calculated in these studies. Absolute value of ADC might not be appropriately used to compare because signal intensity of MRI is influenced by many factors [35]. Hence, it is necessary to take another reference for comparison to reduce the bias. In addition, some studies applied relative value of ADC (ADC ratio), but the reference was differently chosen from brainstem to brain white matter tissue. Based on above findings, difference selection of MRI techniques and parameters may lead to different results among these studies. Development of standard measures of tumor consistency, standard MRI

quantification metrics, and further exploration of MRI technique may improve the predictive ability of neuroimaging for PA in the future.

It has been reported that collagen deposition is a significant pathological feature in fibrous pituitary adenomas of PA [33, 34]. Masson trichrome staining in our study demonstrated that the collagen content in the hard tumor was about five times than that in the soft tumor. Moreover, ADC values for predicting consistency was confirmed by postoperative Masson trichrome staining, which showed that lower ADC ratio was significantly associated with higher collagen content. Therefore, assessing tumor consistency, preoperative DWI characteristics were consistent with intraoperative findings and postoperative histopathological features.

Higher GTR rate might lead to better clinical outcome for patients with PA [6]. Tumor consistency based on intraoperative observation has been reported to be a key determinant of extent of resection in intracranial tumor [15, 39]. However, the correlation between radiologic variable for evaluating tumor Fig. 2 A 47-year-old female with an intermediate pituitary adenoma. The tumor in the sellar region is isointense on coronal T1-weighted imaging (a), hyperintense on coronal T2weighted imaging (b), obviously enhanced on coronal enhanced T1-wighted imaging (c), and relatively isointense on apparent diffusion coefficient map (d). e Pituitary adenoma is confirmed by postoperative hematoxylineosin staining (e), and moderate collagen content (in blue) is found in Masson trichrome staining showed (f)



consistency and extent of resection and recurrence is rarely reported. Our study further discussed the role of DWI in predicting extent of surgical resection and postoperative recurrence/progression. Multivariable logistic regression analysis showed that higher ADC ratio was associated with higher rate of resection, which presented that soft tumor was more likely to be totally removed. Thus, ADC ratio could be used routinely in preoperative evaluation for PA. Our results did not clarify the relationship between ADC ratio and recurrence/progression. Further interventions were recommended for patients with residual tumor after surgery in our hospital. Of 57 patients without GTR, 23 (40.3%) patients were performed with interventions, and statistical analysis showed, compared with patients without interventions, patients with interventions have lower progression rate (32.3% vs 8.7%, P = 0.037;Supplementary table S3). Therefore, due to postoperative interventions for residual PA, progression rate was decreased in our cohort, which may explain why ADC ratio was not effective in predicting recurrence/progression. Long-term followup would be needed to clarify the role of ADC ratio in predicting tumor recurrence/progression.

# Limitations

There were several limitations in the study. First, although the same neurosurgeon used uniform standard to evaluate the tumor consistency and blood flow at surgery, it may still be subjective. More accurate methods should be used in the future study. Second, tumor removal by suction makes it difficult to preserve the same tissue for histopathological assessment as it is for evaluation of ADC value. Third, to reduce the effect of tumor size and heterogeneity on assessment of ADC and CBF value, some types of PA, such as microadenomas, were excluded from our study. Thus, the results may not be generalizable to all patients and should be interpreted with caution. Further studies are required to and thus develop grading system for preoperative risk assessment and clinical decision making.

Fig. 3 A 57-year-old female with a soft pituitary adenoma. The tumor in the sellar region is relatively hypointense on coronal T1-weighted imaging (a), relatively hyperintense on coronal T2-weighted imaging (b), homogeneously enhanced on coronal enhanced T1-wighted imaging (c), and hyperintense on apparent diffusion coefficient map (d). Pituitary adenoma is confirmed by postoperative hematoxylin-eosin staining (e), and scanty collagen content (in blue) is found in Masson trichrome staining showed (f)



Characteristics	Univariate logistic regression (gross-total resection)			Multivariate logistic regression (gross-total resection)			Univariate Cox proportional (recurrence/progression)			Multivariate Cox proportional (recurrence/ progression)		
	OR	95% CI	P value	OR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
Age (years)	1.017	0.988-1.048	0.251	-	-	-	0.978	0.949-1.008	0.151	-	-	-
Sex, female	1.402	0.656-2.994	0.383	-	-	-	0.622	0.274-1.410	0.256	-	-	-
Hormone type (functional PA)	1.877	0.780-4.517	0.160	-	-	-	0.782	0.326-1.876	0.582	-	-	-
Invasive pituitary adenoma	0.414	0.188-0.908	0.028	0.459	0.220-0.960	0.039	2.576	1.124-5.905	0.025	2.728	1.262-5.899	0.011
Tumor size (≥ 40 mm)	0.221	0.096-0.509	0.000	0.233	0.105-0.520	0.000	1.375	0.619-3.053	0.434	-	-	-
ADC ratio	11.726	3.697-37.186	0.000	12.135	4.001-36.804	0.000	0.741	0.295-1.864	0.524	-	-	-
CBF ratio	0.889	0.670-1.181	0.417	-	-	-	0.751	0.456-1.238	0.262	-	-	-

CI confidence interval, PA pituitary adenoma



# Conclusions

ADC ratio of DWI could be used for preoperative assessment of tumor consistency, tumor collagen content, and extent of surgical resection, which might be useful in preoperative planning for patients with PA. Long-term follow-up would be needed to clarify the role of ADC ratio in predicting tumor recurrence/progression.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s10143-020-01469-y.

**Acknowledgments** The authors would like to thank Dr. Zhongliang Hu and Dr. Zhenghao Deng of the Department of Pathology at Xiangya hospital for their assistance with the histopathological assessment.

**Author contributions** W D, Z H, and ZY L contributed to the study conception and design. W D, Z H, and MY Z collected clinical data.GF Z and L L collected radiological data. W D and Z H performed the statistical analysis and drafted the manuscript. All authors contributed to the interpretation of results, all revised the manuscript critically for important intellectual content, and all approved the final manuscript. ZY L is the guarantor.

**Funding** This study was funded by the Natural Science Foundation of Hunan Province of China (Grant No.2018jj6139) and the Innovationoriented Provinces Construction Project of Hunan Province (Grant No. 2019ZK4004).

**Data availability** Data of this study are available from the corresponding author upon reasonable request.

# **Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethics approval** The current study was approved by the ethical committee of our hospital.

**Consent to participate** Informed consent was obtained from all enrolled patients.

**Consent for publication** All authors of this manuscript consent to the publication of the manuscript in Neurosurgical Review journal.

Code availability Not applicable

# References

- Abe T, Iwata T, Kawamura N, Izumiyama H, Ikeda H, Matsumoto K (1997) Staged transsphenoidal surgery for fibrous nonfunctioning pituitary adenomas with suprasellar extension. Neurol Med Chir 37:830–837. https://doi.org/10.2176/nmc.37.830
- Aflorei ED, Korbonits M (2014) Epidemiology and etiopathogenesis of pituitary adenomas. J Neuro-Oncol 117:379– 394. https://doi.org/10.1007/s11060-013-1354-5
- 3. Alimohamadi M, Sanjari R, Shirani M, Alikhani F, Amirjamshidi A (2019) Initial experience with diffusion-weighted imaging to

predict the tumor consistency and surgical success in solid growth hormone producing pituitary macroadenomas. Asian J Neurosurg 14:698–701. https://doi.org/10.4103/ajns.AJNS 56 16

- Alimohamadi M, Sanjari R, Mortazavi A, Shirani M, Moradi Tabriz H, Hadizadeh Kharazi H, Amirjamshidi A (2014) Predictive value of diffusion-weighted MRI for tumor consistency and resection rate of nonfunctional pituitary macroadenomas. Acta Neurochir 156:2245–2252; discussion 2252. https://doi.org/10. 1007/s00701-014-2259-6
- Azab WA, Nasim K, Abdelnabi EA, Yousef W, Najibullah M, Khan T, Zaidan SN, Bokeris AA, Mostafa KH, Geng D (2019) Endoscopic endonasal excision of large and giant pituitary adenomas: radiological and intraoperative correlates of the extent of resection. World Neurosurg 126:e793–e802. https://doi.org/10.1016/ j.wneu.2019.02.151
- Berkmann S, Fandino J, Müller B, Remonda L, Landolt H (2012) Intraoperative MRI and endocrinological outcome of transsphenoidal surgery for non-functioning pituitary adenoma. Acta Neurochir 154:639–647. https://doi.org/10.1007/s00701-012-1285-5
- Bladowska J, Bednarek-Tupikowska G, Sokolska V, Badowski R, Moroń K, Bonicki W, Sąsiadek M (2010) MRI image characteristics of materials implanted at sellar region after transsphenoidal resection of pituitary tumours. Pol J Radiol 75:46–54
- Bladowska J, Biel A, Zimny A, Lubkowska K, Bednarek-Tupikowska G, Sozanski T, Zaleska-Dorobisz U, Sasiadek M (2011) Are T2-weighted images more useful than T1-weighted contrast-enhanced images in assessment of postoperative sella and parasellar region? Med Sci Monit Int Med J Exp Clin Res 17:Mt83–Mt90. https://doi.org/10.12659/msm.881966
- Bladowska J, Zimny A, Guziński M, Hałoń A, Tabakow P, Czyż M, Czapiga B, Jarmundowicz W, Sąsiadek MJ (2013) Usefulness of perfusion weighted magnetic resonance imaging with signalintensity curves analysis in the differential diagnosis of sellar and parasellar tumors: preliminary report. Eur J Radiol 82:1292–1298. https://doi.org/10.1016/j.ejrad.2013.01.033
- Boxerman JL, Rogg JM, Donahue JE, Machan JT, Goldman MA, Doberstein CE (2010) Preoperative MRI evaluation of pituitary macroadenoma: imaging features predictive of successful transphenoidal surgery. AJR Am J Roentgenol 195:720–728. https://doi.org/10.2214/ajr.09.4128
- Cao L, Chen H, Hong J, Ma M, Zhong Q, Wang S (2013) Magnetic resonance imaging appearance of the medial wall of the cavernous sinus for the assessment of cavernous sinus invasion by pituitary adenomas. J Neuroradiol = Journal de Neuroradiologie 40:245– 251. https://doi.org/10.1016/j.neurad.2013.06.003
- 12. Dallapiazza RF, Grober Y, Starke RM, Laws ER Jr, Jane JA Jr (2015) Long-term results of endonasal endoscopic transphenoidal resection of nonfunctioning pituitary macroadenomas. Neurosurgery 76:42–53. https://doi.org/10.1227/neu. 000000000000563
- Fathalla H, Cusimano MD, Di Ieva A, Lee J, Alsharif O, Goguen J, Zhang S, Smyth H (2015) Endoscopic versus microscopic approach for surgical treatment of acromegaly. Neurosurg Rev 38:541–548; discussion 548-549. https://doi.org/10.1007/s10143-015-0613-7
- Guadilla I, Calle D, Lopez-Larrubia P (2018) Diffusion-weighted magnetic resonance imaging. Methods Mol Biol (Clifton, NJ) 1718:89–101. https://doi.org/10.1007/978-1-4939-7531-0\_6
- Itamura K, Chang KE, Lucas J, Donoho DA, Giannotta S, Zada G (2018) Prospective clinical validation of a meningioma consistency grading scheme: association with surgical outcomes and extent of tumor resection. J Neurosurg:1–5. https://doi.org/10.3171/2018.7. Jns1838
- Juraschka K, Khan OH, Godoy BL, Monsalves E, Kilian A, Krischek B, Ghare A, Vescan A, Gentili F, Zadeh G (2014) Endoscopic endonasal transphenoidal approach to large and giant

pituitary adenomas: institutional experience and predictors of extent of resection. J Neurosurg 121:75–83. https://doi.org/10.3171/ 2014.3.Jns131679

- Kinoshita Y, Yamasaki F, Tominaga A, Ohtaki M, Usui S, Arita K, Sugiyama K, Kurisu K (2016) Diffusion-weighted imaging and the apparent diffusion coefficient on 3T MR imaging in the differentiation of craniopharyngiomas and germ cell tumors. Neurosurg Rev 39:207–213; discussion 213. https://doi.org/10.1007/s10143-015-0660-0
- Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610–618. https://doi.org/10.1227/00006123-199310000-00008
- Kondo M, Uchiyama Y (2018) Apparent diffusion coefficient histogram analysis for prediction of prognosis in glioblastoma. J Neuroradiol = Journal de Neuroradiologie 45:236–241. https:// doi.org/10.1016/j.neurad.2017.11.011
- Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, Pieralli S, Giovanelli M (2008) Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 108:525–532. https:// doi.org/10.3171/jns/2008/108/3/0525
- Lv L, Yin S, Zhou P, Hu Y, Chen C, Ma W, Jiang Y, Wang Z, Jiang S (2018) Clinical and pathologic characteristics predicted the postoperative recurrence and progression of pituitary adenoma: a retrospective study with 10 years follow-up. World Neurosurg 118: e428–e435. https://doi.org/10.1016/j.wneu.2018.06.210
- Ma Z, He W, Zhao Y, Yuan J, Zhang Q, Wu Y, Chen H, Yao Z, Li S, Wang Y (2016) Predictive value of PWI for blood supply and T1-spin echo MRI for consistency of pituitary adenoma. Neuroradiology 58:51–57. https://doi.org/10.1007/s00234-015-1591-8
- Maeda M, Maier SE (2008) Usefulness of diffusion-weighted imaging and the apparent diffusion coefficient in the assessment of head and neck tumors. J Neuroradiol = Journal de Neuroradiologie 35:71–78. https://doi.org/10.1016/j.neurad.2008.01.080
- Mascalchi M, Filippi M, Floris R, Fonda C, Gasparotti R, Villari N (2005) Diffusion-weighted MR of the brain: methodology and clinical application. La Radiologia Medica 109:155–197
- Mastorakos P, Mehta GU, Chatrath A, Moosa S, Lopes MB, Payne SC, Jane JA Jr (2019) Tumor to cerebellar peduncle T2-weighted imaging intensity ratio fails to predict pituitary adenoma consistency. J Neurol Surg B, Skull base 80:252–257. https://doi.org/10. 1055/s-0038-1668516
- Mohamed FF, Abouhashem S (2013) Diagnostic value of apparent diffusion coefficient (ADC) in assessment of pituitary macroadenoma consistency. Egypt J Radiol Nucl Med 44:617– 624. https://doi.org/10.1016/j.ejmm.2013.05.012
- Patel KS, Dhawan S, Wang R, Carter BS, Chen JY, Chen CC (2018) Post-operative imaging assessment of non-functioning pituitary adenomas. Acta Neurochir 160:1029–1039. https://doi.org/10. 1007/s00701-018-3491-2
- 28. Pierallini A, Caramia F, Falcone C, Tinelli E, Paonessa A, Ciddio AB, Fiorelli M, Bianco F, Natalizi S, Ferrante L, Bozzao L (2006) Pituitary macroadenomas: preoperative evaluation of consistency with diffusion-weighted MR imaging-initial experience.

Radiology 239:223–231. https://doi.org/10.1148/radiol. 2383042204

- Raverot G, Dantony E, Beauvy J, Vasiljevic A, Mikolasek S, Borson-Chazot F, Jouanneau E, Roy P, Trouillas J (2017) Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification. J Clin Endocrinol Metab 102: 3368–3374. https://doi.org/10.1210/jc.2017-00773
- Schwyzer L, Berberat J, Remonda L, Roelcke U (2015) Susceptibility changes in meningiomas influence the apparent diffusion coefficient in diffusion-weighted MRI. J Neuroradiol = Journal de Neuroradiologie 42:332–337. https://doi.org/10.1016/j. neurad.2015.06.002
- Su CQ, Zhang X, Pan T, Chen XT, Chen W, Duan SF, Ji J, Hu WX, Lu SS, Hong XN (2019) Texture analysis of high b-value diffusionweighted imaging for evaluating consistency of pituitary macroadenomas. J Magn Reson Imaging. https://doi.org/10.1002/ jmri.26941
- Suzuki C, Maeda M, Hori K, Kozuka Y, Sakuma H, Taki W, Takeda K (2007) Apparent diffusion coefficient of pituitary macroadenoma evaluated with line-scan diffusion-weighted imaging. J Neuroradiol = Journal de Neuroradiologie 34:228–235. https://doi.org/10.1016/j.neurad.2007.06.007
- 33. Wang H, Li W, Shi D, Ye Z, Qin F, Guo Y, Yuan X (2009) Expression of TGFbeta1 and pituitary adenoma fibrosis. Br J Neurosurg 23:293-296. https://doi.org/10.1080/ 02688690802617046
- Wang H, Li WS, Shi DJ, Ye ZP, Tai F, He HY, Liang CF, Gong J, Guo Y (2008) Correlation of MMP(1) and TIMP (1) expression with pituitary adenoma fibrosis. J Neuro-Oncol 90:151–156. https://doi.org/10.1007/s11060-008-9647-9
- 35. Wei L, Lin SA, Fan K, Xiao D, Hong J, Wang S (2015) Relationship between pituitary adenoma texture and collagen content revealed by comparative study of MRI and pathology analysis. Int J Clin Exp Med 8:12898–12905
- 36. Yiping L, Ji X, Daoying G, Bo Y (2016) Prediction of the consistency of pituitary adenoma: a comparative study on diffusion-weighted imaging and pathological results. J Neuroradiol = Journal de Neuroradiologie 43:186–194. https://doi.org/10.1016/j. neurad.2015.09.003
- Yiping L, Hui L, Kun Z, Daoying G, Bo Y (2014) Diffusionweighted imaging of the sellar region: a comparison study of BLADE and single-shot echo planar imaging sequences. Eur J Radiol 83:1239–1244. https://doi.org/10.1016/j.ejrad.2014.03.011
- Yunoue S, Tokimura H, Tominaga A, Fujio S, Karki P, Usui S, Kinoshita Y, Habu M, Moinuddin FM, Hirano H, Arita K (2014) Transsphenoidal surgical treatment of pituitary adenomas in patients aged 80 years or older. Neurosurg Rev 37:269–276; discussion 276-267. https://doi.org/10.1007/s10143-013-0509-3
- Zada G, Yashar P, Robison A, Winer J, Khalessi A, Mack WJ, Giannotta SL (2013) A proposed grading system for standardizing tumor consistency of intracranial meningiomas. Neurosurg Focus 35:E1. https://doi.org/10.3171/2013.8.Focus13274

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.